Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors.

Thakore PI, Kwon JB, Nelson CE, Rouse DC, Gemberling MP, Oliver ML, Gersbach CA.

Nat Commun. 2018 Apr 26;9(1):1674. doi: 10.1038/s41467-018-04048-4.

2.

* CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments.

Farhang N, Brunger JM, Stover JD, Thakore PI, Lawrence B, Guilak F, Gersbach CA, Setton LA, Bowles RD.

Tissue Eng Part A. 2017 Aug;23(15-16):738-749. doi: 10.1089/ten.TEA.2016.0441. Epub 2017 Feb 28.

3.

Editing the epigenome: technologies for programmable transcription and epigenetic modulation.

Thakore PI, Black JB, Hilton IB, Gersbach CA.

Nat Methods. 2016 Feb;13(2):127-37. doi: 10.1038/nmeth.3733. Review.

4.

In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Castellanos Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA.

Science. 2016 Jan 22;351(6271):403-7. doi: 10.1126/science.aad5143. Epub 2015 Dec 31.

5.

Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.

Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, Crawford GE, Gersbach CA.

Nat Methods. 2015 Dec;12(12):1143-9. doi: 10.1038/nmeth.3630. Epub 2015 Oct 26.

6.

Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors.

Thakore PI, Gersbach CA.

Methods Mol Biol. 2016;1338:71-88. doi: 10.1007/978-1-4939-2932-0_7.

7.

Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.

Hilton IB, D'Ippolito AM, Vockley CM, Thakore PI, Crawford GE, Reddy TE, Gersbach CA.

Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.

8.

Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy.

Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA.

Nat Commun. 2015 Feb 18;6:6244. doi: 10.1038/ncomms7244.

9.

Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells.

Diekman BO, Thakore PI, O'Connor SK, Willard VP, Brunger JM, Christoforou N, Leong KW, Gersbach CA, Guilak F.

Tissue Eng Part A. 2015 Apr;21(7-8):1261-74. doi: 10.1089/ten.TEA.2014.0240. Epub 2015 Jan 23.

10.

Enhanced MyoD-induced transdifferentiation to a myogenic lineage by fusion to a potent transactivation domain.

Kabadi AM, Thakore PI, Vockley CM, Ousterout DG, Gibson TM, Guilak F, Reddy TE, Gersbach CA.

ACS Synth Biol. 2015 Jun 19;4(6):689-99. doi: 10.1021/sb500322u. Epub 2014 Dec 31.

11.

Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.

Ousterout DG, Kabadi AM, Thakore PI, Perez-Pinera P, Brown MT, Majoros WH, Reddy TE, Gersbach CA.

Mol Ther. 2015 Mar;23(3):523-32. doi: 10.1038/mt.2014.234. Epub 2014 Dec 10.

12.

Roles of type VI collagen and decorin in human mesenchymal stem cell biophysics during chondrogenic differentiation.

Twomey JD, Thakore PI, Hartman DA, Myers EG, Hsieh AH.

Eur Cell Mater. 2014 Mar 25;27:237-50; discussion 249-50.

13.

RNA-guided gene activation by CRISPR-Cas9-based transcription factors.

Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilak F, Crawford GE, Reddy TE, Gersbach CA.

Nat Methods. 2013 Oct;10(10):973-6. doi: 10.1038/nmeth.2600. Epub 2013 Jul 25.

14.

Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients.

Ousterout DG, Perez-Pinera P, Thakore PI, Kabadi AM, Brown MT, Qin X, Fedrigo O, Mouly V, Tremblay JP, Gersbach CA.

Mol Ther. 2013 Sep;21(9):1718-26. doi: 10.1038/mt.2013.111. Epub 2013 Jun 4. Erratum in: Mol Ther. 2013 Nov;21(11):2130.

Supplemental Content

Loading ...
Support Center